financetom
Business
financetom
/
Business
/
Texas sues Tylenol makers J&J and Kenvue, claiming they hid drug's autism risks
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Texas sues Tylenol makers J&J and Kenvue, claiming they hid drug's autism risks
Oct 28, 2025 7:09 AM

Oct 28 (Reuters) - The makers of Tylenol, Johnson &

Johnson ( JNJ ) and Kenvue, were sued on Tuesday by

Texas Attorney General Ken Paxton, who accused them of knowingly

hiding the drug's links to autism and attention deficit

hyperactivity disorder.

Paxton, a Republican, sued five weeks after Republican

President Donald Trump said

using Tylenol during pregnancy can cause autism in

children. Trump is not a doctor, and his claim is unproven and

not backed by scientific evidence.

Johnson & Johnson ( JNJ ) sold Tylenol for more than six decades,

and its former Kenvue unit has sold it since 2023 after being

spun off. The pain reliever is known generically as

acetaminophen.

Kenvue has repeatedly defended Tylenol's safety, and in a

statement said it would defend against Paxton's lawsuit.

"Acetaminophen is the safest pain reliever option for

pregnant women as needed throughout their entire pregnancy,"

Kenvue said. "We are deeply concerned by the perpetuation of

misinformation on the safety of acetaminophen."

In a separate statement, Johnson & Johnson ( JNJ ) did not comment

on Paxton's lawsuit, and said Kenvue is responsible for "all

rights and liabilities associated with the sale of its

over-the-counter products, including Tylenol."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Meta grants senior executives stock awards to retain talent
Meta grants senior executives stock awards to retain talent
Mar 24, 2026
March 24 (Reuters) - Meta Platforms ( META ) on Tuesday granted restricted stock units and stock options for some of its senior executives, including CFO Susan Li and Chief Technology Officer Andrew Bosworth, tying them to performance and aggressive share price targets as it looks to retain top talent. Stock awards are typically issued to reward employees, retain top...
Meta grants senior executives stock awards to retain talent
Meta grants senior executives stock awards to retain talent
Mar 24, 2026
March 24 (Reuters) - Meta Platforms ( META ) on Tuesday granted restricted stock units and stock options for some of its senior executives, including CFO Susan Li and Chief Technology Officer Andrew Bosworth, tying them to performance and aggressive share price targets as it looks to retain top talent. Stock awards are typically issued to reward employees, retain top...
Fluid release ignited blast, fire at Valero refinery, filing shows
Fluid release ignited blast, fire at Valero refinery, filing shows
Mar 24, 2026
* Valero completed Port Arthur refinery shutdown on Tuesday * Fire extinguished at Texas refinery * No injuries reported from blast, blaze By Erwin Seba HOUSTON, March 24 (Reuters) - A release of fluid set off an explosion and ensuing fire that forced the temporary shutdown of Valero Energy Corp's ( VLO ) 380,000-barrel-per-day (bpd) oil refinery in Port Arthur,...
Merck nears $6 billion all-cash deal to buy Terns Pharma, FT reports
Merck nears $6 billion all-cash deal to buy Terns Pharma, FT reports
Mar 24, 2026
March 24 (Reuters) - Merck ( MRK ) is nearing a roughly $6 billion all-cash deal to buy biotech firm Terns Pharma , the Financial Times reported on Tuesday, citing people familiar with the matter. Talks between Merck ( MRK ) and Terns were at an advanced stage and a deal could be reached in the coming days, the report...
Copyright 2023-2026 - www.financetom.com All Rights Reserved